Recent results in the treatment of chronic B virus hepatitis

Of the drugs evaluated to date for the therapy of chronic hepatitis B, only α-interferons have gained wide acceptance as single-agent therapy. In HBeAg-positive carriers, treatment must be carried out for 4–6 months on an alternate-day basis and dosage should be not less than 5 million Usu2 of body surface. Oriental patients, children, immunodeficient and highly viremic patients are less likely to respond. Patients given combination therapy (with steroids, antivirals, stimulators of the immune system) do not appear to benefit from the association in comparison with treatment with interferon alone. In most patients (60–80%) with atypical chronic type B infections (anti-HBe-positive, HBV-DNA-positive, intrahepatic HBcAg), HBV-DNA becomes negative and transaminases normalize during interferon treatment; however, many (80%) experience a relapse of viremia and disease during follow-up. Side effects are usually minor (flu-like symptoms), but in a minority of patients, major adverse events have also been reported. α-Interferon is effective in inhibiting viral replication in a significant number of patients with chronic type B hepatitis, but new therapeutic regimens and a better selection of patients are needed in order to induce persistent remissions and reduce the cost/benefit ratio.